

List of Suggested Topics

- Resensitizing resistant bacteria
- New classes of antibacterial agents
- Multi-drug resistant *Mycobacterium tuberculosis*
- TB and HIV coinfection
- The microbiome and its impact on health and illness
- Mannan synthesis inhibitors-a promising group of antifungals
- Vaccines against HIV
- Vaccines against malaria
- Vaccines against melanoma
- Zika virus vaccines
- Ebola virus treatment and vaccines
- Poliovirus vaccine
- Development of vaccines against *Helicobacter pylori*
- Lyme disease vaccine
- Hepatitis A vaccine
- Development of a Shigella vaccine
- Efforts to improve typhoid vaccines
- Vaccines against cytomegalovirus
- Vaccines against the Epstein-Barr virus
- Development of a vaccine against leprosy
- Yellow fever vaccine
- Development of a vaccine against the Herpes virus
- Vaccines against group A Streptococci
- Mold allergies: what's the real story?
- Development and improvement of vaccines against tuberculosis
- Plague vaccines
- Bioterrorism: smallpox or other agents
- Vaccines for Alzheimer's disease
- Vaccines for insulin-dependent diabetes mellitus
- Vaccines to prevent Staphylococcus aureus infections
- Superantigens
- Streptococcus virulence factors and potential for vaccines and inhibitor design
- Management of E. coli O157:H7 infection
- Potent new azoles (not yet approved)
- Severe acute respiratory syndrome (SARS)
- Viruses and type 1 diabetes
- Treatment of schistosomiasis
- New approaches for malaria treatment
- Rifaximin for hepatic encephalopathy
- Antibiotics for irritable bowel syndrome?
- Treatment of septic shock
- Treatment of XDR-TB
- Treatment of bite wounds
- Treatment of Acinetobacter infection
- Retapamulin, our first pleuromutilin
- Treatment of invasive candidiasis
- Treatment of invasive aspergillosis
- Zygomycete infections